Angom RS et al.23 observed that patient-derived GBM cells expressing shRNA against VEGF or NRP-1 attenuated cancer stem cell markers and inhibited tumor-initiating cell neurosphere-forming capacity and migration. This evidence concerns the gene NRP1 and glioblastoma.